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OBJECTIVE — Hepatic lipase (HL) is involved in the metabolism of several lipoproteins and
may contribute to the atherogenic lipid profile in type 2 diabetes. Little is known about the effect
of cholesterol synthesis inhibitors on HL activity in relation to sex and the hepatic lipase gene, the
LIPC promoter variant in type 2 diabetes. Therefore, we studied the effect of atorvastatin 10 mg
(A10) and 80 mg (A80) on HL activity in 198 patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS — Patients (aged 45–75 years, without mani-
fest coronary artery disease, total cholesterol 4.0–8.0 mmol/l, and fasting triglycerides [TG]
1.5–6.0 mmol/l) were included in a double-blind, randomized, placebo-controlled trial for 30
weeks (Diabetes Atorvastatin Lipid Intervention study).
RESULTS — HL activity at baseline was significantly higher in our population compared with
an age-matched control group without type 2 diabetes (406  150 vs. 357  118 units/l). HL
activity in men versus women (443  158 vs. 358  127 units/l), in carriers of the LIPC C/C
allele versus carriers of the T/T allele (444 142 vs. 227 96 units/l), and in Caucasians versus
blacks (415  150 vs. 260  127 units/l) all differed significantly (P  0.001). Atorvastatin
dose-dependently decreased HL (A10,11%; A80,22%; both P 0.001). Neither sex nor the
LIPC C3T variation influenced the effect of atorvastatin on HL activity.
CONCLUSIONS — Sex, LIPC promoter variant, and ethnicity significantly contribute to the
baseline variance in HL activity. Atorvastatin treatment in diabetic dyslipidemia results in a
significant dose-dependent decrease in HL activity, regardless of sex or the LIPC promoter
variant.
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H epatic lipase (HL) is involved in themetabolism of several lipoproteins(1) and is a key player in HDL me-
tabolism (2,3). Hydrolysis of phospholip-
ids and triglycerides by HL leads to the
conversion of large, buoyant HDL2 to
small, dense HDL3 and may induce cho-
lesterol (ester) flux to the liver (4,5). In
this way, HL is involved in reverse choles-
terol transport and is a major determinant
of plasma HDL concentration (6,7). HL
also plays a role in the formation of small,
dense LDL and contributes to the expres-
sion of the LDL subclass phenotype (8,9).
Finally, HL is proposed to be involved in
postprandial lipid clearing (10). Obvi-
ously, HL activity seems to be central in
the metabolism of lipoproteins strongly
associated with coronary artery disease
(CAD) risk in type 2 diabetes. Zambon et
al. (11) identified HL as a focal point for
the development and treatment of CAD.
Genetic variation, sex, and abdominal fat
mass affect HL activity in humans (12–
15).
In the human hepatic lipase gene
(LIPC), variants are found that affect
lipase activity (16 –18). Besides rather
rare variants leading to complete HL de-
ficiency (19,20), common base substitu-
tions in the proximal LIPC promoter
affect HL activity up to twofold (15,21,
22). Four base substitutions, 250
G3A, 514 C3T, 710 T3C, and
763 A3G, were found to be com-
pletely linked (23). Together, they consti-
tute two alleles, indicated as the LIPC C
and T allele, after the C3T variant at
514 bp, which is also indicated as
C–480T. The C and T alleles are associ-
ated with high and low HL activity, re-
spectively. The frequency of both alleles
varies highly among different ethnic pop-
ulations (21,24,25). The C allele is the
most common allele in Caucasians,
whereas the T allele is the major allele in
black Americans. Asians have an interme-
diate frequency. Besides genetic variance,
HL lipase activity is also hormonally af-
fected. In particular, sex hormones influ-
ence LIPC expression and are believed to
be responsible for HL activity being lower
in women than in men (13,25,26). An in-
crease in HL activity is associated with an
increase in abdominal fat mass, BMI, and
fasting insulin and fasting plasma triglyc-
eride levels (27). These correlations are
reflected in a high HL activity in type 2
diabetes.
A change in HL activity may also be
induced by hypolipidemic drugs. In
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males, but not in females, we found a de-
crease in HL activity during atorvastatin
treatment of familial hypercholesterol-
emia (28). Zambon et al. (29) reported a
drop in HL activity in participants of the
Familial Atherosclerosis Treatment Study
(FATS) during treatment with lovastatin-
colestipol and niacin-colestipol. Interest-
ingly, in both groups the effect of
treatment on HL activity was strongly de-
pendent on the presence of the LIPC T
allele. HL activity was lowered less in car-
riers of the T allele compared with non-
carriers (30). Thus, sex and genotype of
the LIPC promoter may determine the ef-
ficacy of the statin treatment. Earlier stud-
ies (31–34) showed a beneficial effect of
3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase inhibitors on the
incidence of cardiovascular events in type
2 diabetes. Also, although atorvastatin, a
powerful statin, effectively reduces total
cholesterol and triglyceride concentra-
tions, no data describing its effect on HL
activity in type 2 diabetes are currently
available. Therefore, we conducted a dou-
ble-blind, placebo-controlled, random-
ized, 30-week study to evaluate the effect
of atorvastatin 10 vs. 80 mg on HL activity
in subjects with type 2 diabetes. Sex and
the LIPC C3T variation as possible mod-
ifiers of the atorvastatin treatment effect
were considered in this study.
RESEARCH DESIGN AND
METHODS
Study population
This study is part of the Diabetes Atorva-
statin Lipid Intervention (DALI) study.
DALI is a randomized, double-blind, pla-
cebo-controlled, multicenter study con-
ducted in the Netherlands. The subjects
and methods have been described in de-
tail (35).
In short, 217 patients (aged 45 to 75
years, with type 2 diabetes) participating
in the DALI study were randomized to
placebo, atorvastatin 10 mg (A10), or
atorvastatin 80 mg (A80) during 30
weeks, to evaluate the effect on lipid me-
tabolism, endothelial function, coagula-
tion, and inflammatory parameters. The
main inclusion criteria were plasma tri-
glycerides between 1.5 and 6.0 mmol/l,
total cholesterol between 4.0 and 8.0
mmol/l, and no history of coronary heart
disease. Postheparin lipase activity blood
samples of 198 DALI patients were avail-
able and evaluated in this study.
Analytical methods
Blood samples were drawn (after 12 h of
fasting) at baseline and after 30 weeks, the
end of the study. Standard lipid variables
(total cholesterol, HDL cholesterol, and
triglycerides [TG]), free fatty acids
(FFAs), plasma glucose, HbA1c, and HL
activity were measured. Cholesterol and
TG were determined by enzymatic color-
imetric methods on a Hitachi 911 auto-
matic analyzer (Boehringer Mannheim,
Mannheim, Germany). Plasma HDL cho-
lesterol was measured by a direct enzy-
matic HDL cholesterol method, after
precipitation of VLDL and LDL by addi-
tion of manganese chloride. LDL choles-
terol was estimated by the Friedewald
formula (36). Fasting plasma glucose was
determined on a Hitachi 917 analyzer us-
ing an ultraviolet-hexokinase method
(cat. no. 18766899; Boehringer Mann-
heim). HbA1c was determined by high-
performance liquid chromatography,
using the Bio-Rad Variant method (cat.
no. 270-0003).
Postheparin plasma HL activity
HL activity was measured using an immu-
nochemical method as described previ-
ously (37) in plasma collected 20 min
after contralateral intravenous adminis-
tration of heparin (50 IU/kg) (Leo Phar-
maceutical Products, Weesp, The
Netherlands). HL control subjects con-
sisted of 93 male and female volunteers,
aged 45 to 75 years, without type 2 dia-
betes or hypertriglyceridemia.
DNA analysis
Genotyping of the LIPC gene for the C3T
variance was carried out by determination
of the G3A base substitution at –250 bp
(38). Primers for the PCR amplification
were 5-GAT ACT TTG TTA GGG AAG
ACT GCC-3 and 5-GGA TCA CCT CTC
AAT GGG TC-3. Amplification was car-
ried out in a 25-l reaction mixture with
an initial denaturation at 95°C for 5 min,
followed by 31 cycles of amplification at
95°C for 30 s, annealing at 55°C for 30 s,
and extension at 72°C for 60 s, with a final
extension at 72°C, using Goldstar Taq
polymerase (Eurogentec). Fifteen micro-
liters of the PCR mix was digested with
the restriction enzyme DraI during 2 h at
37°C, followed by electrophoresis on a
2% agarose gel. The nondigested PCR
product had a length of 560 bp. After di-
gestion, the –250G variant yielded two
products of 449 and 111 bp. Digestion of
the250A variant yielded a major prod-
uct of 335 bp and minor products of 114
and 111 bp. It was shown previously that
the –250G variant is 100% linked to the C
variant at –514 and the –710T and –763A
variants upstream in the LIPC promoter
(18). These variants collectively form the
LIPC C allele. The variant sequence con-
taining 250 A, 514 T, 710 C, and
763 G are indicated as LIPC T allele.
Statistical analysis
Analyses were performed by SPSS for
Windows (release 9.0). Mean differences
between the study groups were analyzed
using analysis of covariance (ANCOVA),
adjusted for baseline levels of each treat-
ment group and study location. Interven-
tion effects were also further adjusted for
additional potential confounders, using
ANCOVA. The Student’s t test was used to
test significance between baseline and 30-
week follow-up. Continuous variables are
presented as mean values with the stan-
dard deviation (SD). P values0.05 were
considered statistically significant.
RESULTS
Patient characteristics
The baseline characteristics of the 198 pa-
tients are shown in Table 1.
There were no significant differences
in characteristics between the three
groups, except for the duration of diabe-
tes, which was shorter in the placebo than
the A80 group (P 0.05). Fasting glucose
and HbA1c at baseline were relatively
high, but equal in all groups. Fasting glu-
cose did not change during the study. The
A80 group had a slight increase in HbA1c
levels (8.4  1.1% to 8.6  1.3%; P 
0.05), whereas in patients using A10 and
placebo, HbA1c levels decreased slightly
(both 8.3  1.2% to 8.1  1.2%; P 
0.05).
Atorvastatin effect on lipids and
lipoproteins
At baseline, plasma lipids and lipopro-
teins were similar in all three groups (Ta-
ble 1). As described before (35),
administration of A10 and A80 resulted in
significant reductions (25% and 35%, re-
spectively) of plasma TG levels (both P
0.001) and significant, dose-dependent
reductions of total cholesterol (30% and
40%, respectively; both P  0.001) and
LDL (41% and 52%, respectively; both
P 0.001). HDL cholesterol levels signif-
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icantly increased, independent of dose,
during atorvastatin treatment by 5–6%
(P  0.01).
HL activity in type 2 diabetes
Baseline HL in the DALI population was
significantly higher than in age-matched,
nondiabetic control subjects without hy-
pertriglyceridemia (406  150 units/l,
n  198, vs. 357  118 units/l, n  93;
P  0.001). This was due to a significant
increase in HL activity in the male patients
compared with the male control subjects
(443  158 vs. 397 125 units/l; P 
0.001). Female DALI patients had a com-
parable HL activity compared with female
control subjects (358  127 vs. 328 
105 units/l). Sex, LIPC genotype, ethnic-
ity, and BMI were all significant and inde-
pendent predictors of HL activity,
demonstrated by stepwise linear regres-
sion. The LIPC genotype contributed
13%, sex 8%, ethnicity 4%, and BMI 3%
to the variance in HL activity (adjusted R2
of the model  0.28, P  0.0001).
Atorvastatin effect on postheparin
lipase activity
Mean HL activity at baseline was compa-
rable between the three study groups. In
the placebo group, there was no signifi-
cant reduction in HL activity at the end of
the study. HL activity decreased in the
A10 group by 11% (P 0.001) and in the
A80 group by 22% (P 0.001) (Table 2).
The additional reduction in HL activity by
A80 compared to A10 was highly signifi-
cant (P  0.005).
Atorvastatin effect on postheparin
lipase activity in men and women
Because HL activity in the DALI partici-
pants was significantly higher in men than
in women (443  158 units/l, n  107,
vs. 358 127 units/l, n 91; P 0.001),
we analyzed men and women separately.
The effect on HL activity by atorvastatin
was not influenced by sex differences.
Treatment with atorvastatin 10 or 80 mg
reduced HL activity similarly, 11 and
22%, in both men and women (Table 2).
Atorvastatin effect on hepatic lipase
activity in the LIPC promoter variant
The C3T variance in the LIPC promoter
is a strong, significant predictor of HL ac-
tivity; therefore we analyzed carriers and
noncarriers of the T allele separately.
In the DALI study population, 55.0%
of the patients were homozygous for the
LIPC C allele, 37.4% were heterozygous
for the T allele, and 7.6% were homozy-
gous for the T allele, leading to a T allele
frequency of 0.262. At baseline, the pres-
ence of the T variant significantly affected
HL activity (Table 3). In heterozygous
carriers of the T allele, HL activity was
19% lower, and in homozygous carriers
of the T allele, 49% lower, than in C allele
homozygotes (P  0.0001).
The T allele lowered the baseline HL
activity in men and women. Male het-
erozygous and homozygous T allele car-
riers, respectively, had 20% and 57%
lower HL lipase activity than C homozy-
gotes. Women had 16% and 37%, respec-
tively, lower lipase activity (Table 3). In
men and women, the frequency of the T
allele was comparable, 0.252 vs. 0.278.
Homozygous carriers of the C allele
and heterozygous carriers of the T allele
showed similar percentage reductions in
HL activity after atorvastatin treatment
(Table 4). In both groups, A10 resulted in
a 10–12% decrease and A80 in a 21–22%
decrease in HL activity (P  0.001 vs.
placebo; dose-dependent, P  0.005).
Four of the 15 T/T homozygotes were as-
signed to the A10 treatment group, 3 to
the A80 group, and 8 placebo. After ator-
vastatin treatment, HL activities were
available in only five patients. A10 treat-
Table 1—Baseline characteristics
Placebo
Atorvastatin
10 mg 80 mg
n 65 67 66
Male sex (%) 48 62 54
Age (years) 58.5  7.3 59.4  7.6 60.5  7.8
Diabetes duration (years) 9.5  6.1 12.2  7.7 13.2  8.5*
Diabetes treatment (%)
Diet 3.1 1.5 0
Tablets 40.6 50.0 43.9
Insulin 31.3 27.3 27.3
Combination 25.0 21.2 28.8
BMI (kg/m2) 31.9  6.1 30.1  3.8 30.6  4.5
WHR 0.99  0.1 1.00  0.1 1.00  0.1
Hypertension (%) 48 49 62
Current smoking (%) 58 66 70
Fasting glucose (mmol/l) 10.5  3.6 10.4  3.0 10.6  3.0
HbA1c (%) 8.3  1.2 8.3  1.2 8.4  1.1
Total cholesterol (mmol/l) 6.1  0.9 5.9  0.8 6.0  1.0
LDL cholesterol (mmol/l) 3.7  0.9 3.6  0.8 3.7  0.9
HDL cholesterol (mmol/l) 1.05  0.2 1.06  0.3 1.04  0.2
Triglycerides (mmol/l) 2.64  0.9 2.50  0.9 2.82  1.1
Continuous data are means  SD. *P  0.05 between atorvastatin 80 mg and placebo group.
Table 2—Hepatic lipase activity (units/l) after 30 weeks of treatment
Patients n Placebo
Atorvastatin
10 mg 80 mg
All 198
Baseline 406  156 402  152 410  138
30 weeks 382  146 361  149* 313  112*
Males 107
Baseline 449  138 429  154 451  143
30 weeks 425  128 390  150* 343  98*
Females 71
Baseline 358  131 360  155 356  109
30 weeks 343  125 318  138* 278  120*
Continuous data are means SD. *P 0.001, significantly different from baseline in each treatment group.
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ment lowered HL activity in two cases
(249 to 216 units/l, 15%; 349 to 259
units/l, 25%). In one case, A10 did not
reduce HL activity (319 to 349 units/l, 9%
increase). In both subjects assigned to
A80, HL activity was lowered (248 to 218
units/l, 12%; 266 to 200 units/l,
25%). A10 lowered HL activity to a sim-
ilar degree in male and female C/C and
C/T carriers (10–13%). A80 resulted in a
further reduction of 16% in the female
C/C homozygotes and 31% in the female
C/T heterozygotes. In men, the additional
decrease was 27 and 19%, respectively,
not significantly different from the values
in women.
Ethnic differences, LIPC
polymorphism, and HL activity
It has been reported that the prevalence of
LIPC C and T alleles strongly varies
among subjects with different ethnic her-
itage, thereby affecting HL activity. Thus,
we studied the influence of ethnic heter-
ogeneity in our study population. Mean
HL activity at baseline was significantly
lower among Asian (n  10), Mediterra-
nean (n 9), and black (n 11) patients
compared with Caucasians (n 168), re-
spectively (350  95, 269  124, and
260  127 units/l vs. 415  150 units/l;
P 0.01). The T allele frequency was very
high in black (0.590) and Asian (0.400)
patients. Caucasians and Mediterranean
patients had T allele frequencies of 0.235
and 0.222, respectively. At baseline, HL
activity was strongly influenced by the
LIPC gene variance in all ethnic groups.
HL activity was significantly higher in CC
homozygotes than in CT heterozygotes or
TT homozygotes. To study a possible ef-
fect of ethnic background, Caucasians
were separately analyzed for the effect of
atorvastatin in relation with the LIPC ge-
notype. Atorvastatin had an effect in Cau-
casians similar to that of the whole study
population (data not shown). The other
groups were not analyzed separately, be-
cause of the small numbers.
CONCLUSIONS — This prospec-
tive, randomized study demonstrated a
dose-dependent decrease in HL activity
by atorvastatin in type 2 diabetes patients.
HL activity decreased 11 and 22% after
treatment with atorvastatin 10 and 80 mg,
respectively (P 0.001). In type 2 diabe-
tes, HL is considered an important factor
in the development of the atherogenic
lipid profile. Our study results are the first
published effects in type 2 diabetes of
low- versus high-dose statin influencing
HL activity. Sex and the LIPC CT poly-
morphism both influence HL activity.
Men have a higher HL activity than
women because of a number of endoge-
nous factors, such as central adiposity and
sex steroid hormones (14,15,26,39,40).
Recently, Carr et al. (41) also demon-
strated that intra-abdominal fat is a major
component of the sex difference in HL
activity. In our diabetic study population
as well, men exhibited higher HL activity
than women. Whereas the male patients
tended to have a higher HL activity com-
pared with control subjects without dia-
betes, in the female patients HL activity
was similar to control values. Baseline HL
activity correlated significantly with
waist-to-hip ratio (WHR) (R 0.20, P
0.004). Men had a higher WHR com-
pared with women (P  0.001), and the
increased HL activity in the men may be
partially explained by this increased
WHR. Atorvastatin treatment abolished
the correlation between HL activity and
WHR. In preliminary results, we found
that fatty acids may stimulate LIPC ex-
pression in HepG2 cells and that this ef-
fect is abolished by atorvastatin (27). Our
present results are in line with these ob-
servations and suggest that increased HL
activity in our male patients may be due to
stimulation of HL expression by increased
supply of fatty acids derived from a higher
abdominal fat mass as reflected in the
high WHR. By interfering with the stim-
ulation of HL by FFAs, atorvastatin may
then lower HL activity with the conse-
quent loss of the association between HL
activity and WHR. Besides sex, genetic
variation of the LIPC promoter strongly
affected HL activity at baseline and con-
tributed 13% to the variance in HL activ-
ity. In the whole study population, LIPC
T/T homozygotes had a 50% lower HL
activity than the C/C homozygotes. Ator-
vastatin lowered HL activity in all subjects
independent of sex and genotype. Zam-
bon et al. (30) found an attenuating effect
of the T allele on HL lowering by hypo-
lipidemic drug treatment in hyperlipid-
emic patients. In the present study, the
already low dose of statin decreased HL
activity in all genotypes similarly. It is
possible that atorvastatin has a higher in-
trinsic capacity to lower HL than other
hypolipidemic drugs. Alternatively, HL
activity in type 2 diabetes may be affected
in a different way than in patients without
Table 3—Effect of the LIPC C3 T variance on HL activity (units/l) at baseline
Total Males Females
CC genotype 444  142 489  131 385  137
n 109 61 48
CT genotype 358  135† 390  158† 324  95†‡
n 74 38 36
TT genotype 227  96† 212  56† 244  131†
n 15 8 7
Data are means  SD. *P  0.001 vs. males; †P  0.001 vs noncarriers; ‡P  0.03 vs. males.
Table 4—LIPC C3 T variance and HL activity (units/l) after 30 weeks of treatment
Genotype n Placebo
Atorvastatin
10 mg 80 mg
CC genotype 109
Baseline 437  124 448  140 447  129
30 weeks 441  139 402  156* 348  98*
CT genotype 74
Baseline 352  144 357  121 366  157
30 weeks 349  137 319  128* 280  128*
TT genotype 15
Baseline 224  76 306  104 257  76
30 weeks 236  137 273  34 209  45
Data are means  SD. *P  0.001, significantly different from baseline in each treatment group.
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diabetes. HL activity also varies among
different ethnic groups. Our results
showed that the allele frequency for the
LIPC T allele in black patients was much
higher than in Caucasian patients, consis-
tent with earlier studies (21). This higher
prevalence of the T allele in black patients
completely accounted for the lowered HL
activity at baseline compared with Cauca-
sian patients (260 vs. 415 units/l). How-
ever, Nie et al. (24) stated that 97% of
African Americans have at least one HL
allele that is associated with low HL activ-
ity. The effect of ethnic background on
the frequency of the T allele underscores
the importance of this factor, when LIPC
allele frequency between groups, with or
without diabetes, is compared. The T al-
lele frequency in our Caucasian subjects
was 0.235. Jansen et al. (16) reported a
frequency of 0.189 in a healthy, nondia-
betic, Caucasian population. Without
correction for ethnicity, T allele frequency
in the patients with type 2 diabetes ap-
peared to be higher than in Caucasians
without diabetes (0.262 vs. 0.189).
The clinical significance of our find-
ings needs further investigation. HL
seems to be involved in the metabolism of
almost all lipoprotein classes. Among
other things, it may modulate LDL and
HDL metabolism and postprandial lipid
clearing. How and to what extent HL low-
ering by atorvastatin in type 2 diabetes
affects these processes, and thereby CAD
risk, is presently unknown.
In conclusion, sex, LIPC promoter
variant, and ethnicity greatly contribute
to the baseline variance in HL activity in
type 2 diabetes. This should be taken into
account in studies evaluating the effect of
lipid-lowering therapy on HL expression.
Atorvastatin treatment results in a dose-
dependent decrease in HL activity, re-
gardless of sex or the LIPC promoter
variant.
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